Jet Biotech announced that the cumulative deviation value of the company's stock closing price increase reached 30% for 3 consecutive trading days, which is an abnormal fluctuation in stock trading. After self-inspection and investigation, the controlling shareholders and actual controllers showed that the company's daily business conditions were normal, there were no major changes, no significant information that should be disclosed but not disclosed, and the directors, supervisors, controlling shareholders, and actual controllers did not trade the company's shares during the change period. In the first half of 2026, the company achieved operating income of 277 million yuan, a year-on-year increase of 3.47%; net profit to mother was 208.16,600 yuan, a year-on-year decrease of 55.08%. Investors are kindly requested to invest rationally and be aware of risks.

Jet Biotech announced that the cumulative deviation value of the company's stock closing price increase reached 30% for 3 consecutive trading days, which is an abnormal fluctuation in stock trading. After self-inspection and investigation, the controlling shareholders and actual controllers showed that the company's daily business conditions were normal, there were no major changes, there was no significant information that should be disclosed but not disclosed, and the directors, supervisors, controlling shareholders, and actual controllers did not trade the company's shares during the period of change. In the first half of 2026, the company achieved operating income of 277 million yuan, a year-on-year increase of 3.47%; net profit to mother was 208.16,600 yuan, a year-on-year decrease of 55.08%. Investors are kindly requested to invest rationally and be aware of risks.